TRIM25 and central nervous system cancer: Consistently, data analysis from TCGA cohort also revealed higher TRIM25 expression in HCC patients was associated with poor clinical outcome as well as shorter disease-free survival times (Fig. 7f, g), which also observed in patients with breast cancer and lower grade glioma (Supplementary Fig. 6d, e).